万邦医药
(301520)
| 流通市值：10.27亿 | | | 总市值：30.52亿 |
| 流通股本：2242.30万 | | | 总股本：6666.67万 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 151,823,897.33 | 179,294,435.57 | 173,284,439.23 | 175,323,414.01 |
| 结算备付金 | 0 | 0 | - | - |
| 拆出资金 | 0 | 0 | - | - |
| 衍生金融资产 | 0 | 0 | - | - |
| 应收票据及应收账款 | 77,574,171.26 | 75,904,327.29 | 82,876,652.14 | 66,725,035.15 |
| 其中：应收票据 | 9,829,689.57 | 12,012,254.92 | 13,245,445.63 | 9,390,935.98 |
| 应收账款 | 67,744,481.69 | 63,892,072.37 | 69,631,206.51 | 57,334,099.17 |
| 应收款项融资 | 0 | 0 | - | - |
| 预付款项 | 10,840,590.77 | 9,942,873.55 | 10,410,522.95 | 10,847,125.57 |
| 应收保费 | 0 | 0 | - | - |
| 应收分保账款 | 0 | 0 | - | - |
| 应收分保合同准备金 | 0 | 0 | - | - |
| 其他应收款合计 | 7,254,026.28 | 3,990,203.95 | 4,586,966.87 | 3,789,828.58 |
| 其中:应收利息 | 0 | 0 | - | - |
| 应收股利 | 0 | 0 | - | - |
| 买入返售金融资产 | 0 | 0 | - | - |
| 存货 | 736,765.05 | 1,960,203.84 | 840,279.68 | 1,022,292.34 |
| 合同资产 | 111,011,954.21 | 100,578,246.82 | 94,397,398.53 | 93,246,661.61 |
| 一年内到期的非流动资产 | 0 | 0 | - | - |
| 其他流动资产 | 8,069,095.92 | 7,596,175.47 | 60,006,274.56 | 59,088,852.9 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,373,385,553.45 | 1,402,736,641.42 | 1,394,558,447.3 | 1,373,171,254.81 |
| 非流动资产: | | | | |
| 发放委托贷款及垫款 | 0 | 0 | - | - |
| 债权投资 | 0 | 0 | - | - |
| 其他债权投资 | 0 | 0 | - | - |
| 长期应收款 | 0 | 0 | - | - |
| 长期股权投资 | 0 | 0 | - | - |
| 其他权益工具投资 | 0 | 0 | - | - |
| 其他非流动金融资产 | 3,000,000 | 3,000,000 | - | - |
| 投资性房地产 | 6,887,191.4 | 6,985,054.61 | 7,082,917.82 | 7,180,781.03 |
| 固定资产 | 172,032,190.09 | 174,767,718.24 | 177,272,635.61 | 167,267,355.24 |
| 在建工程 | 6,475,740.71 | 1,665,843.83 | - | - |
| 生产性生物资产 | 0 | 0 | - | - |
| 油气资产 | 0 | 0 | - | - |
| 使用权资产 | 0 | 0 | - | - |
| 无形资产 | 11,394,853.41 | 11,572,652.41 | 15,237,571.89 | 11,438,770.88 |
| 开发支出 | 0 | 0 | - | 4,282,396.15 |
| 商誉 | 0 | 0 | - | - |
| 长期待摊费用 | 2,302,372.82 | 2,746,119.17 | 4,254,534.02 | 4,542,554.69 |
| 递延所得税资产 | 249,397.59 | 0 | 200,290.53 | 269,948.15 |
| 其他非流动资产 | 476,761.23 | 333,984.38 | 1,237,147.79 | 2,991,812.68 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 202,818,507.25 | 201,071,372.64 | 205,285,097.66 | 197,973,618.82 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,576,204,060.7 | 1,603,808,014.06 | 1,599,843,544.96 | 1,571,144,873.63 |
| 流动负债: | | | | |
| 短期借款 | 0 | 0 | - | - |
| 向中央银行借款 | 0 | 0 | - | - |
| 吸收存款及同业存放 | 0 | 0 | - | - |
| 拆入资金 | 0 | 0 | - | - |
| 交易性金融负债 | 0 | 0 | - | - |
| 衍生金融负债 | 0 | 0 | - | - |
| 应付票据及应付账款 | 39,620,377.34 | 37,833,222.06 | 38,617,305.36 | 32,497,872.91 |
| 其中：应付票据 | 0 | 0 | - | - |
| 应付账款 | 39,620,377.34 | 37,833,222.06 | 38,617,305.36 | 32,497,872.91 |
| 预收款项 | 0 | 0 | - | - |
| 合同负债 | 15,068,353.17 | 19,699,559.13 | 15,588,512.09 | 18,072,085.26 |
| 卖出回购金融资产款 | 0 | 0 | - | - |
| 应付手续费及佣金 | 0 | 0 | - | - |
| 应付职工薪酬 | 5,117,491.54 | 13,330,686.85 | 14,356,500.12 | 10,228,303.99 |
| 应交税费 | 577,122.37 | 1,007,038.47 | 1,292,481.64 | 3,026,754.06 |
| 其他应付款合计 | 1,830,823.06 | 1,884,736.18 | 1,128,877.04 | 2,691,400.12 |
| 其中:应付利息 | 0 | 0 | - | - |
| 应付股利 | 0 | 0 | - | - |
| 应付分保账款 | 0 | 0 | - | - |
| 保险合同准备金 | 0 | 0 | - | - |
| 代理买卖证券款 | 0 | 0 | - | - |
| 代理承销证券款 | 0 | 0 | - | - |
| 一年内到期的非流动负债 | 0 | 0 | - | - |
| 其他流动负债 | 882,100.89 | 960,710.18 | 906,410.42 | 994,881.92 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 63,096,268.37 | 74,715,952.87 | 71,890,086.67 | 67,511,298.26 |
| 非流动负债: | | | | |
| 长期借款 | 0 | 0 | - | - |
| 应付债券 | 0 | 0 | - | - |
| 优先股 | 0 | 0 | - | - |
| 永续债 | 0 | 0 | - | - |
| 租赁负债 | 0 | 0 | - | - |
| 长期应付款 | 0 | 0 | - | - |
| 长期应付职工薪酬 | 0 | 0 | - | - |
| 预计负债 | 0 | 0 | - | - |
| 递延收益 | 7,115,148.73 | 7,413,327.01 | 7,876,516.23 | 8,119,690.91 |
| 递延所得税负债 | 8,371,304.41 | 8,310,227.58 | 11,603,037.24 | 9,804,503.28 |
| 其他非流动负债 | 0 | 0 | - | - |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 15,486,453.14 | 15,723,554.59 | 19,479,553.47 | 17,924,194.19 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 78,582,721.51 | 90,439,507.46 | 91,369,640.14 | 85,435,492.45 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 66,666,667 | 66,666,667 | 66,666,667 | 66,666,667 |
| 其他权益工具 | 0 | 0 | - | - |
| 优先股 | 0 | 0 | - | - |
| 永续债 | 0 | 0 | - | - |
| 资本公积 | 1,037,419,668.53 | 1,037,419,668.53 | 1,037,419,668.53 | 1,037,419,668.53 |
| 减:库存股 | 7,740,624 | 2,838,596 | - | - |
| 其他综合收益 | 0 | 0 | - | - |
| 专项储备 | 0 | 0 | - | - |
| 盈余公积 | 40,578,122.09 | 40,526,803.38 | 33,073,818.61 | 33,073,818.61 |
| 一般风险准备 | 0 | 0 | - | - |
| 未分配利润 | 360,697,505.57 | 371,593,963.69 | 371,313,750.68 | 348,549,227.04 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,497,621,339.19 | 1,513,368,506.6 | 1,508,473,904.82 | 1,485,709,381.18 |
| 少数股东权益 | 0 | 0 | - | - |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,497,621,339.19 | 1,513,368,506.6 | 1,508,473,904.82 | 1,485,709,381.18 |
| 负债和股东权益合计 | 1,576,204,060.7 | 1,603,808,014.06 | 1,599,843,544.96 | 1,571,144,873.63 |
| 公告日期 | 2025-04-22 | 2025-04-22 | 2024-10-25 | 2024-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |